{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:47:21Z","timestamp":1792234041603,"version":"4.4.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.28634","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T23:30:08Z","timestamp":1608334208000},"page":"e2028634","source":"Crossref","is-referenced-by-count":94,"title":["Assessment of Plasma Amyloid-\u03b2<sub>42\/40<\/sub>and Cognitive Decline Among Community-Dwelling Older Adults"],"prefix":"10.1001","volume":"3","author":[{"given":"Kelly Virecoulon","family":"Giudici","sequence":"first","affiliation":[{"name":"Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipe","family":"de Souto Barreto","sequence":"additional","affiliation":[{"name":"Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, France"},{"name":"UPS\/Inserm UMR1027, University of Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Guyonnet","sequence":"additional","affiliation":[{"name":"Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, France"},{"name":"UPS\/Inserm UMR1027, University of Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"Division of Biostatistics, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall John","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[{"name":"Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, France"},{"name":"UPS\/Inserm UMR1027, University of Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MAPT\/DSA Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"issue":"4","key":"zoi200917r1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi200917r2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u00df concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"zoi200917r3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u00df biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"3","key":"zoi200917r4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JAD-190714","article-title":"Amyloid-\u00df as a blood biomarker for Alzheimer\u2019s disease: a review of recent literature.","volume":"73","author":"Wang","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"zoi200917r5","first-page":"169","article-title":"Plasma biomarkers of AD emerging as essential tools for drug development: an EU\/US CTAD Task Force report.","volume":"6","author":"Bateman","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"zoi200917r6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/archneurol.2011.1841","article-title":"Plasma amyloid-\u00df as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.","volume":"69","author":"Koyama","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"zoi200917r7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","article-title":"The future of blood-based biomarkers for Alzheimer\u2019s disease.","volume":"10","author":"Henriksen","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"9","key":"zoi200917r8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer Disease-related \u00df-amyloid status.","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi200917r9","first-page":"34","article-title":"Plasma A\u00df42\/40 ratio detects early stages of Alzheimer\u2019s Disease and correlates with CSF and neuroimaging biomarkers in the AB255 Study.","volume":"6","author":"P\u00e9rez-Grijalba","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"zoi200917r10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u00df 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease.","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"17","key":"zoi200917r11","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u00df-amyloid 42\/40 predicts current and future brain amyloidosis.","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"zoi200917r12","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.neurobiolaging.2015.06.023","article-title":"Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects.","volume":"36","author":"Llado-Saz","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"3","key":"zoi200917r13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","article-title":"Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.","volume":"64","author":"Graff-Radford","year":"2007","journal-title":"Arch Neurol"},{"issue":"10","key":"zoi200917r14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archneurol.2009.207","article-title":"Ten-year change in plasma amyloid beta levels and late-life cognitive decline.","volume":"66","author":"Okereke","year":"2009","journal-title":"Arch Neurol"},{"issue":"12","key":"zoi200917r15","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/archneurol.2010.189","article-title":"Plasma \u00df-amyloid and cognitive decline.","volume":"67","author":"Cosentino","year":"2010","journal-title":"Arch Neurol"},{"issue":"3","key":"zoi200917r16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2010.1995","article-title":"Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline.","volume":"305","author":"Yaffe","year":"2011","journal-title":"JAMA"},{"key":"zoi200917r17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2020.01.007","article-title":"Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project.","volume":"89","author":"Verberk","year":"2020","journal-title":"Neurobiol Aging"},{"issue":"1","key":"zoi200917r18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/JAD-180321","article-title":"Plasma A\u00df42 as a biomarker of prodromal Alzheimer\u2019s disease progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog\/E-ADNI Study.","volume":"69","author":"Albani","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi200917r19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JAD-180970","article-title":"Identification and preliminary validation of a plasma profile associated with cognitive decline in dementia and at-risk individuals: a retrospective cohort analysis.","volume":"67","author":"Iulita","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi200917r20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-017-0319-x","article-title":"The clinical significance of plasma clustering and A\u00df in the longitudinal follow-up of patients with Alzheimer\u2019s disease.","volume":"9","author":"Hsu","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi200917r21","first-page":"13","article-title":"MAPT Study: a multidomain approach for preventing Alzheimer\u2019s disease: design and baseline data.","volume":"1","author":"Vellas","year":"2014","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"zoi200917r22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol"},{"issue":"12","key":"zoi200917r23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"1","key":"zoi200917r24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ab.2013.04.031","article-title":"Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics.","volume":"440","author":"Mawuenyega","year":"2013","journal-title":"Anal Biochem"},{"issue":"3","key":"zoi200917r25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mas.v39.3","article-title":"The Skyline ecosystem: informatics for quantitative mass spectrometry proteomics.","volume":"39","author":"Pino","year":"2020","journal-title":"Mass Spectrom Rev"},{"issue":"3","key":"zoi200917r26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"zoi200917r27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia.","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"issue":"4","key":"zoi200917r28","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1097\/01.wad.0000213873.25053.2b","article-title":"ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials.","volume":"20","author":"Galasko","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"zoi200917r29","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.neurobiolaging.2011.09.004","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: plasma A\u00df40 and A\u00df42, and genetic variants.","volume":"32","author":"Mayeux","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"2","key":"zoi200917r30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2011-101977","article-title":"Meta-analysis of plasma amyloid-\u00df levels in Alzheimer\u2019s disease.","volume":"26","author":"Song","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"zoi200917r31","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u00df-amyloid in Alzheimer\u2019s disease and vascular disease.","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"zoi200917r32","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers.","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi200917r33","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1021\/acschemneuro.9b00095","article-title":"Potential value of plasma amyloid-\u00df, total tau, and neurofilament light for identification of early Alzheimer\u2019s disease.","volume":"10","author":"Shi","year":"2019","journal-title":"ACS Chem Neurosci"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2774284\/giudici_2020_oi_200917_1607543079.80317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:21:30Z","timestamp":1670368890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2774284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.28634","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]}}}